Summary of Jabil (JBL) FY Conference Call - May 13, 2025 Company Overview - **Company**: Jabil (JBL) - **Industry**: Electronics Manufacturing Services (EMS) Key Points and Arguments Macro Economic Concerns - There is a sense of relief among customers regarding recession fears, with the administration's efforts seen as effective in preventing a significant downturn [3][5][6] - Jabil's diversified portfolio across various end markets, including healthcare and digital commerce, positions the company well to manage through economic fluctuations [4][5] Supply Chain and Tariff Management - Jabil has regionalized its supply chain, producing in-country for local consumption, which mitigates risks associated with tariff volatility [7][8] - The company is not currently seeing significant shifts in business due to tariffs, as customers are cautious about the costs and risks of relocating operations [8] Capacity and Geographic Flexibility - Approximately 35% to 40% of Jabil's capacity is located in the Americas, with current utilization around 75-80%, indicating room for growth [16][18] - The company has recently opened a facility in St. Petersburg, Florida, and has the capability to expand in the U.S. and Mexico as needed [16][18] Margin Improvement Strategies - Jabil aims to increase its margin from 5.4% to 6% or 6.5% in the near future, driven by portfolio diversification, vertical integration, and operational efficiencies [22][23][24] - The company is focusing on higher-margin businesses and has made tuck-in acquisitions to enhance its service offerings [24][25] Growth in Cloud and Data Center Infrastructure - Jabil has increased its revenue guidance for the second half of the fiscal year by $1 billion, driven by strong demand from hyperscale customers and capital equipment business [28] - The company is confident in continued spending from cloud customers, viewing it as an "arms race" among hyperscalers [28][29] Automotive Sector Challenges - The automotive segment faces headwinds from tariffs and reduced demand for electric vehicles (EVs), but Jabil is diversifying its customer base and product offerings to mitigate risks [44][45] - The company has added new OEM customers in China, which is expected to provide growth opportunities in the EV space [46][48] Healthcare Market Opportunities - Jabil is significantly larger than its nearest competitor in the healthcare market and is focused on expanding its share of wallet through organic growth and acquisitions [56][57] - The company recently acquired Pharmaceutical International Incorporated, enhancing its capabilities in pharmaceutical delivery systems [58] Semiconductor Capital Equipment - Jabil's semiconductor capital equipment business is performing well, with strong growth driven by key customers like NVIDIA [62] - The company anticipates a cyclical recovery in the semiconductor industry within the next twelve months [63] Networking and Communications - The networking segment is experiencing slower growth due to exiting low-margin businesses, but there are positive trends in Ethernet and liquid cooling technologies [65][66] Digital Commerce Growth - Jabil is seeing growth in digital commerce, particularly in automation and robotics for retail environments, with expectations for continued expansion in this area [67][68] Future Outlook - Jabil's path to achieving higher margins is not solely dependent on revenue growth but also on optimizing product mix and operational efficiencies [69][70] - The company is well-positioned for future growth across various sectors, including healthcare, cloud infrastructure, and automotive, despite current economic challenges [49][50][56]

Financial Data and Key Metrics Changes - Net sales for Q3 totaled $375 million, representing a 10% decline year over year when excluding the divested AT and M business [8][12] - Gross margin rate in Q3 was 7.2%, a 70 basis point decline compared to 7.9% in the same period last year [12] - Adjusted net income in Q3 was $6.8 million or $0.27 per diluted share, down from $9.8 million or $0.39 per diluted share in the same quarter last year [16] Business Line Data and Key Metrics Changes - Medical segment net sales were $115 million, up 2% year over year, driven by non-recurring consignment inventory sales [8][9] - Automotive segment net sales were $173 million, a 14% decrease year over year, representing 46% of total company sales [10] - Industrial segment net sales were $86 million, down 15% year over year, representing 23% of total company sales [10][11] Market Data and Key Metrics Changes - Sales in the Medical market increased, while the Automotive and Industrial markets experienced declines [8][10] - The automotive business is heavily concentrated in North America and China, with growth noted in Europe due to a new braking platform [10] Company Strategy and Development Direction - The company is focusing on expanding its presence in the medical contract manufacturing organization (CMO) sector, with a new manufacturing facility in Indianapolis [6][9] - The strategy includes utilizing cash generated from EMS operations to invest in the CMO sector, with expectations for organic revenue growth over time [7][9] - The company aims to improve its global capacity utilization by closing the Tampa facility and streamlining operations [23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to growth through emerging medical technologies and high-level assemblies [23] - The current tariff environment presents uncertainty, impacting the timing of recovery in the core EMS business [20][22] - Management reiterated guidance for fiscal year 2025, expecting to be at the high end of sales and operating income ranges [19] Other Important Information - Cash flow generated by operating activities in the quarter was $30.9 million, marking the fifth consecutive quarter of positive cash flow [16] - The company has $304.6 million in short-term liquidity available at the end of Q3 [18] - The company invested $3 million to repurchase 175,000 shares of common stock during the quarter [19] Q&A Session Summary Question: Details about the new facility in Indianapolis - The new facility provides more space for growth in the medical CMO sector and is leased to minimize upfront costs [25][26] Question: Impact of the existing facility's sale - It is too early to determine the potential value of the existing facility, with a transition period of two to three years expected [30] Question: Trends in open orders or backlog - The greatest increase in backlog was seen in the medical vertical, followed by industrial and automotive [32] Question: Orders pulled into March due to tariffs - Management is uncertain if orders were pulled forward due to tariffs but is monitoring customer feedback [36] Question: Operating expenses trends for the rest of the year - SG&A expenses are expected to rise as investments are needed to prepare for growth [41] Question: Short-term moves in gross margin and operating income - Next quarter is expected to be similar to Q3, with conservative estimates due to market uncertainties [48] Question: Demand environment in medical - The investment in the new facility was made to capture larger business opportunities in the medical CMO sector [50] Question: Inventory management and cash conversion - There is still room for improvement in cash conversion days, with ongoing efforts to manage inventory effectively [53]

Financial Data and Key Metrics Changes - Net sales for Q2 totaled $357 million, a 15% decrease year over year, with a 13% decline when excluding AT and M [8][14] - Adjusted operating income for Q2 was $13.3 million, or 3.7% of net sales, compared to $19.1 million, or 4.5% of net sales, in the previous year [16] - Adjusted net income in Q2 was $7.4 million, or $0.29 per diluted share, down from $9.8 million, or $0.39 per diluted share, in the same quarter last year [17] - Cash flow generated from operating activities was $29.5 million, marking the fourth consecutive quarter of positive cash flow [17][18] - Inventory levels decreased by $149 million, or 33%, year over year, ending the quarter at $306.2 million [18] Business Line Data and Key Metrics Changes - Automotive net sales were $193 million, a 4% decrease year over year, representing 54% of total company sales [9] - Medical net sales were $84 million, a 22% decrease year over year, accounting for 23% of total company sales [10] - Industrial net sales were $81 million, down 20% year over year, also representing 23% of total company sales [12] Market Data and Key Metrics Changes - North America and Europe experienced double-digit declines, while Asia saw an increase in sales [8] - The automotive business in China showed strong performance, with record production rates, contrasting with declining volumes in North America [9] Company Strategy and Development Direction - The company is strategically repositioning for growth, focusing on divesting non-core assets and enhancing facility utilization [6][7] - There is an increased focus on the medical CMO sector, with plans to expand manufacturing capabilities [12][27] - The company is exploring opportunities in emerging medical technologies and high-level assemblies [27] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a sustained period of declining customer demand and revised expectations for the full fiscal year [6][7] - The company is optimistic about future growth but recognizes that necessary changes will take time [7][27] - Management is actively working with customers to navigate the impacts of tariffs and supply chain challenges [22][24] Other Important Information - The company has amended its credit facility, enhancing its capital structure and providing additional liquidity for investments [19][20] - A total of $97.7 million has been returned to shareholders through share repurchases since October 2015, with $22.3 million remaining on the repurchase program [20][21] Q&A Session Summary Question: What is the impact of tariffs on production decisions? - Management indicated that even with a 25% tariff, it remains more cost-effective for most products to be manufactured in Mexico [30] Question: How is inventory reduction trending? - Management noted that inventory is expected to continue decreasing over the next six to twelve months as they manage customer agreements [35] Question: What is the current utilization rate in Jasper? - The utilization rate in Jasper is around 65%, with discussions ongoing about moving additional work from Tampa to Jasper [43] Question: Is the revised guidance driven by a specific vertical? - The revised guidance reflects broad-based softness across all verticals, although the automotive sector is holding steady due to strength in Asia [46] Question: What changes are being made to focus on the medical vertical? - The company has restructured to combine its drug delivery business with the core EMS medical vertical to enhance collaboration and capabilities [54]